Gemtuzumab is a monoclonal IgG4-?? antibody specifically targeting the CD33 antigen, predominantly expressed on leukemic myeloblasts in acute myeloid leukemia (AML). This antibody serves as a foundational component for the synthesis of the antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. This conjugate is composed of Gemtuzumab linked to a cytotoxic derivative of Calicheamicin, a potent antibiotic known for its antitumor activity. Gemtuzumab ozogamicin is primarily utilized in research focused on the therapeutic targeting and treatment modalities of acute myeloid leukemia.
Gemtuzumab is a monoclonal IgG4-?? antibody specifically targeting the CD33 antigen, predominantly expressed on leukemic myeloblasts in acute myeloid leukemia (AML). This antibody serves as a foundational component for the synthesis of the antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. This conjugate is composed of Gemtuzumab linked to a cytotoxic derivative of Calicheamicin, a potent antibiotic known for its antitumor activity. Gemtuzumab ozogamicin is primarily utilized in research focused on the therapeutic targeting and treatment modalities of acute myeloid leukemia.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
